The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin

Xenobiotica

Volumn 43, Issue 7, 2013, Pages 579-591

  Kim, Ji Eon ^a   Cho, Hyun Jong ^b   Kim, Jung Sun ^c   Shim, Chang Koo ^a   Chung, Suk Jae ^a   Oak, Min Ho ^d   Yoon, In Soo ^d   Kim, Dae Duk ^a  

^a Seoul National University   (South Korea)

^b Kangwon National University   (South Korea)

^c Dongseo University   (South Korea)

^d Mokpo National University   (South Korea)

Author keywords

Bioavailability; Caco 2 cells; Doxorubicin; Intestinal absorption; Paracellular transport; Rats

Indexed keywords

CYTOCHROME P450 3A4; DOXORUBICIN; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STABILITY; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHILICITY; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; MALE; MEASUREMENT; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; DOXORUBICIN; HUMANS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84878862760     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.751140     Document Type: Article

References (54)

1. Adson A, Raub TJ, Burton PS, et al. (1994). Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J Pharm Sci 83:1529-36. (Pubitemid 24348320)
2. Altenberg GA, Vanoye CG, Horton JK, et al. (1994). Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci USA 91:4654-57. (Pubitemid 24177707)
3. Artursson P, Karlsson J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-5.
4. Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci 89:429-42.
5. Bansal T, Mishra G, Jaggi M, et al. (2009). Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 36:580-90.
6. Bromberg L, Alakhov V. (2003). Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 88:11-22. (Pubitemid 36175538)
7. Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-5. (Pubitemid 28524594)
8. Choi JS, Piao YJ, Kang KW. (2011). Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607-13.
9. Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacoki-netics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543-52. (Pubitemid 44726394)
10. Choubey J, Bajpai AK. (2010). Investigation on magnetically controlled delivery of doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin. J Mater Sci Mater Med 21:1573-86.
11. Cusler EL. (1986). Diffusion: mass transfer in fluid systems. New York: Cambridge University Press.
12. De Mario MD, Ratain MJ. (1999). Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557-667.
13. Fagerholm U. (2007). Prediction of human pharmacokinetics- gastrointestinal absorption. J Pharm Pharmacol 59:905-16.
14. Feng SS, Chien S. (2003). Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 58:4087-114. (Pubitemid 37164365)
15. Gan LS, Hsyu PH, Pritchard JF, et al. (1993). Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm Res 10:1722-5. (Pubitemid 24000355)
16. Garnick MB, Ensminger WD, Israel MA. (1979). A clinical pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res 39:4105-10. (Pubitemid 10189142)
17. Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York: Marcel Dekker.
18. Gustafson DL, Thamm DH. (2010). Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. J Vet Intern Med 24:579-86.
19. Hrishikesh M, Nitya S, Tapobrata L, et al. (2007). A comparative study on the molecular descriptors for predicting drug-likeness of small molecules. Bioinformation 3:384-8.
20. Kakumanu VK, Arora V, Bansal AK. (2006). Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. Int J Pharm 317:155-60. (Pubitemid 43959838)
21. Kalaria DR, Sharma G, Beniwal V, et al. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26:492-501.
22. Ke W, Zhao Y, Huang R, et al. (2008). Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci 97:2208-16.
23. Kivistö KT, Kroemer HK, Eichelbaum M. (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-30. (Pubitemid 26005556)
24. Lee HJ, Chiou WL. (1989). Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 6:833-9. (Pubitemid 20012232)
25. Lee HJ, Paik WH, Lee MG. (1995). Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 89:165-78.
26. Le Lay K, Myon E, Hill S, et al. (2007). Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 8:145-51. (Pubitemid 46742894)
27. Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-58.
28. Nakamura T, Sakaeda T, Ohmoto N, et al. (2002). Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcino-mas. Drug Metab Dispos 30:4-6. (Pubitemid 34016933)
29. ONS Clinical Practice Committee (1999). Cancer chemotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society.
30. Pade V, Stavchansky S. (1997). Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 14:1210-5. (Pubitemid 27432545)
31. Rushing DA, Raber SR, Rodvold KA, et al. (1994). The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834-41. (Pubitemid 24237462)
32. Ryberg M, Nielsen D, Skovsgaard T, et al. (1998). Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-8. (Pubitemid 28506760)
33. Saitoh R, Sugano K, Takata N, et al. (2004). Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res 21:749-55. (Pubitemid 39011295)
34. Schellens JH, Malingré MM, Kruijtzer CM, et al. (2000). Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12:103-10.
35. Schwarzbach MH, Eisold S, Burguete T, et al. (2002). Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol 20:1211-8.
36. Shen Q, Lin Y, Handa T, et al. (2006). Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 313:49-56.
37. Siissalo S, Laitinen L, Koljonen M, et al. (2007). Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 67:548-54. (Pubitemid 47211922)
38. Son HK, Choi JS. (2009). Effects of morin on the bioavailability of doxorubicin for oral delivery in rats. J Kor Pharm Sci 39:243-8.
39. Soucek P, Gut I. (1992). Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22:83-103.
40. Stephens RH, O'Neill CA, Warhurst A, et al. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-91. (Pubitemid 32112489)
41. Takahashi K, Murakami T, Kamata A, et al. (1994). Pharmacokinetic analysis of the absorption enhancing action of decanoic acid and its derivatives in rats. Pharm Res 11:388-92. (Pubitemid 24117357)
42. Troutman MD, Thakker DR. (2003a). Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 20:1192-9. (Pubitemid 36951844)
43. Troutman MD, Thakker DR. (2003b). Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210-24. (Pubitemid 36951846)
44. van Asperen J, van Tellingen O, Beijnen JH. (2000). The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28:264-7. (Pubitemid 30137049)
45. van Breemen RB, Li Y. (2005). Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 1:175-85.
46. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, et al. (2000). Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 11:207-14. (Pubitemid 30616443)
47. van Meer G, Simons K. (1986). The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J 5:1455-64.
48. Varma MV, Panchagnula R. (2005). Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. 2005. Eur J Pharm Sci 25:445-53. (Pubitemid 40853872)
49. Watanabe Y, Nakai H, Hoshiai H. (2005). The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide. Curr Med Res Opin 21:363-8.
50. Wils P, Phung-Ba V, Warnery A, et al. (1994). Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528-30. (Pubitemid 24318161)
51. Yamaguchi S, Zhao YL, Nadai M, et al. (2006). Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 50:80-7. (Pubitemid 43042906)
52. Yoon IS, Choi MK, Kim JS, et al. (2011). Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41:243-51.
53. Yu L, Zeng S. (2007). Transport characteristics of zolmitriptan in a human intestinal epithelial cell line Caco-2. J Pharm Pharmacol 59:655-60. (Pubitemid 47051108)
54. Zhang Z, Feng SS. (2006). Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27:262-70. (Pubitemid 41278528)